Skip to search formSkip to main contentSkip to account menu

Neoantigen-based Glioblastoma Vaccine

Known as: NeoVax (TM) Glioblastoma Vaccine, Personalized Neoantigen Glioblastoma Vaccine 
A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
4535Background: 35% of stage IIIB/C Gastric cancer patients will recurrent after D2 gastrectomy within one year. Mutation-derived… 
2020
2020
3134Background: T-cell targeting of mutation-derived epitopes (neoantigens) has been demonstrated to drive anti-tumor responses… 
2019
2019
Targeting a mutant NPM1-derived neoantigen has antitumor activity against AML cells. 
2019
2019
..........................................................................................................................................2 Introduction .....................................................................................................................................4 Methods Part I: Characterization of the immune response following personalized neoantigen-based vaccination .........................................................................................................................11 Part II: Identification of neoantigen-reactive T cell receptors and their cognate antigens using a streamlined cloning and expression system ..........................................................15 Results Part I: Characterization of the immune response following personalized neoantigen-based vaccination ........................................................................................................................19 Part II: Identification of neoantigen-reactive T cell receptors and their cognate antigens using a streamlined cloning and expression system .........................................................28 Discussion .....................................................................................................................................34 Conclusions ...................................................................................................................................42 Suggestions for Future Work ........................................................................................................43 Lay Summary ................................................................................................................................46 References .....................................................................................................................................47 Supplement ...................................................................................................................................53 
2018
2018
2020Background: The impact of individualized neoepitope vaccination targeting neoantigens arising from tumor-specific mutations… 
2017
2017
Immunotherapy has emerged as a novel and promising strategy for cancer treatment, while available markers for immunotherapy have… 
2011
2011
Introduction Mesothelioma is incurable and new treatment strategies are urgently needed. It has long been recognised that… 
1989
1989
Highly immunogenic (Imm+) murine tumor cell variants can engender a strong tumor-specific, cross-protective immune response… 
1972
1972
This paper describes the appearance of neoantigens in fibrosarcoma cells of the Syrian Hamster during transformation with the SV…